NEW YORK (GenomeWeb News) – Mitochondrial DNA diagnostic test development firm Mitomics today announced a non-exclusive deal with Bostwick Laboratories for the marketing and distribution of the Prostate Core Mitomic Test in the US.
The urologic pathology laboratory will market the test under the name ProstaClear Mitomic Test.
Mitomics' test is based on the Mitomic Technology for detecting whether a deletion in mtDNA may be indicative of disease. The method works by determining the load in the mtDNA of a biological sample and the identity of the mtDNA. The mtDNA of the sample is then compared to a database of interpopulation and intrapopulation variations and deletions associated with cancer.
Mitomics' Prostate Core Mitomic Test is PCR-based. According to the Thunder Bay, Ontario-based firm, the test achieves a sensitivity of 84 percent and a negative predictive value of 91 percent.
Robert Poulter, president and CEO of Mitomics, said in a statement that the deal with Bostwick builds on the "strong momentum" following the launch of the test in March, and Bostwick's "established network within the urologic pathology community will be invaluable, providing patients and physicians greater access" to the prostate cancer testing technology.
Financial and other terms of the agreement were not disclosed.
In the spring, Mitomics announced a deal with QDx Pathology Services for the development, marketing, and processing of a test also based on the Prostate Core Mitomic Test.